Total Payments
$1,714
2024 Payments
$433.50
Companies
17
Transactions
103
Medicare Patients
1,336
Medicare Billing
$85,829
Payment Breakdown by Category
Food & Beverage$1,714 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,714 | 103 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $866.91 | 54 | $0 (2024) |
| ABBVIE INC. | $268.01 | 15 | $0 (2024) |
| Lilly USA, LLC | $197.34 | 12 | $0 (2024) |
| GlaxoSmithKline, LLC. | $59.07 | 2 | $0 (2022) |
| Abbott Laboratories | $51.53 | 2 | $0 (2023) |
| Medtronic, Inc. | $42.82 | 2 | $0 (2023) |
| GENZYME CORPORATION | $30.95 | 2 | $0 (2021) |
| Clarus Therapeutics Inc. | $28.64 | 3 | $0 (2021) |
| Teva Pharmaceuticals USA, Inc. | $25.02 | 2 | $0 (2022) |
| Sunovion Pharmaceuticals Inc. | $23.98 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $433.50 | 23 | Novo Nordisk Inc ($233.19) |
| 2023 | $328.25 | 20 | Novo Nordisk Inc ($147.68) |
| 2022 | $414.93 | 24 | Novo Nordisk Inc ($271.42) |
| 2021 | $537.27 | 36 | Novo Nordisk Inc ($214.62) |
All Payment Transactions
103 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/05/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: Diabetes | ||||||
| 10/15/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $24.56 | General |
| Category: Diabetes | ||||||
| 10/10/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $15.81 | General |
| Category: NEUROSCIENCE | ||||||
| 10/01/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $17.68 | General |
| Category: Diabetes | ||||||
| 07/23/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $21.50 | General |
| Category: NEUROSCIENCE | ||||||
| 07/18/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Obesity | ||||||
| 07/17/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $22.19 | General |
| Category: Diabetes | ||||||
| 06/04/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $23.84 | General |
| Category: NEUROSCIENCE | ||||||
| 05/24/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $12.63 | General |
| Category: Diabetes | ||||||
| 05/07/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $22.92 | General |
| Category: Diabetes | ||||||
| 04/19/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $17.35 | General |
| Category: Obesity | ||||||
| 04/09/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $20.45 | General |
| Category: NEUROSCIENCE | ||||||
| 03/26/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $19.71 | General |
| Category: Diabetes | ||||||
| 03/14/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $19.55 | General |
| Category: Obesity | ||||||
| 03/08/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $15.48 | General |
| 03/01/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $17.56 | General |
| Category: NEUROSCIENCE | ||||||
| 03/01/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $17.35 | General |
| Category: Obesity | ||||||
| 02/20/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $15.35 | General |
| Category: Respiratory | ||||||
| 02/06/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $22.94 | General |
| Category: Diabetes | ||||||
| 01/30/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $16.23 | General |
| Category: NEUROSCIENCE | ||||||
| 01/24/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $22.72 | General |
| Category: Diabetes | ||||||
| 01/19/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $15.24 | General |
| Category: Obesity | ||||||
| 01/18/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $14.78 | General |
| Category: NEUROSCIENCE | ||||||
| 12/07/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $13.18 | General |
| Category: Diabetes | ||||||
| 10/13/2023 | PFIZER INC. | PREVNAR 20 (Biological), COMIRNATY, ABRYSVO | Food and Beverage | In-kind items and services | $21.35 | General |
| Category: VACCINES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 393 | 633 | $57,598 | $23,158 |
| 2022 | 10 | 372 | 525 | $57,983 | $20,710 |
| 2021 | 11 | 380 | 510 | $68,587 | $28,802 |
| 2020 | 5 | 191 | 296 | $41,251 | $13,159 |
Total Patients
1,336
Total Services
1,964
Medicare Billing
$85,829
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 87 | 164 | $27,224 | $10,661 | 39.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 79 | 118 | $13,216 | $5,795 | 43.8% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2023 | 32 | 38 | $4,750 | $1,911 | 40.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 27 | 27 | $4,482 | $1,577 | 35.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 16 | 16 | $4,048 | $1,494 | 36.9% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2023 | 19 | 40 | $1,080 | $648.80 | 60.1% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 23 | 24 | $1,128 | $471.24 | 41.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 27 | 31 | $992.00 | $244.04 | 24.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 34 | 48 | $240.00 | $235.20 | 98.0% |
| 81003 | Automated urinalysis test | Office | 2023 | 24 | 30 | $150.00 | $66.00 | 44.0% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 12 | 47 | $188.00 | $38.16 | 20.3% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 13 | 50 | $100.00 | $16.50 | 16.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 89 | 154 | $25,564 | $9,391 | 36.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 70 | 92 | $10,304 | $4,431 | 43.0% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2022 | 61 | 70 | $8,750 | $3,566 | 40.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 27 | 27 | $6,831 | $1,564 | 22.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 28 | 28 | $4,648 | $1,120 | 24.1% |
| 71046 | X-ray of chest, 2 views | Office | 2022 | 14 | 15 | $705.00 | $262.62 | 37.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 18 | 24 | $768.00 | $194.90 | 25.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 31 | 36 | $180.00 | $106.59 | 59.2% |
| 81003 | Automated urinalysis test | Office | 2022 | 22 | 25 | $125.00 | $55.50 | 44.4% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2022 | 12 | 54 | $108.00 | $18.23 | 16.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 85 | 174 | $28,884 | $12,974 | 44.9% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2021 | 72 | 81 | $10,125 | $4,156 | 41.0% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 46 | 46 | $7,726 | $3,038 | 39.3% |
About Reza Hatefi, PAC
Reza Hatefi, PAC is a Physician Assistant healthcare provider based in Wake Forest, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1114960036.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Reza Hatefi, PAC has received a total of $1,714 in payments from pharmaceutical and medical device companies, with $433.50 received in 2024. These payments were reported across 103 transactions from 17 companies. The most common payment nature is "Food and Beverage" ($1,714).
As a Medicare-enrolled provider, Hatefi has provided services to 1,336 Medicare beneficiaries, totaling 1,964 services with total Medicare billing of $85,829. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty Physician Assistant
- Location Wake Forest, NC
- Active Since 06/14/2006
- Last Updated 02/25/2021
- Taxonomy Code 363A00000X
- Entity Type Individual
- NPI Number 1114960036
Products in Payments
- Rybelsus (Drug) $363.02
- Ozempic (Drug) $297.56
- UBRELVY (Drug) $133.55
- Wegovy (Drug) $120.71
- QULIPTA (Drug) $99.16
- MOUNJARO (Drug) $69.43
- SHINGRIX (Biological) $59.07
- ZEPBOUND (Drug) $54.79
- DUPIXENT (Biological) $50.77
- TRULICITY (Drug) $44.50
- Saxenda (Drug) $37.16
- RYBELSUS (Drug) $32.98
- JATENZO (Drug) $28.64
- EMGALITY (Drug) $28.62
- PROCLAIM (Device) $27.34
- AJOVY (Biological) $25.02
- INTELLIS (Device) $24.19
- Proclaim IPG (Device) $24.19
- GEMTESA (Drug) $23.98
- VRAYLAR (Drug) $23.45
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Physician Assistant Doctors in Wake Forest
Brenda Thomas, P.a, P.A
Physician Assistant — Payments: $2,408
Physician Assistant $2,408
Mrs. Carolyn Solak, Pa-C, PA-C
Physician Assistant — Payments: $2,029
Physician Assistant $2,029
Katherine Gambino, Pa-C, PA-C
Physician Assistant — Payments: $1,868
Physician Assistant $1,868
Ravi Singh, Pa-C, PA-C
Physician Assistant — Payments: $1,494
Physician Assistant $1,494
Eric Castaneda, Pa-C, PA-C
Physician Assistant — Payments: $1,086
Physician Assistant $1,086
Laurie Dunne, Pa, PA
Physician Assistant — Payments: $909.97
Physician Assistant $909.97